Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 20:51 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

ClinicalTrials.gov · NCT01888744 · Registry updated: 2013-06-28

Condition / research focus: Reproductive Endocrinology; Fertility; Optimal Stimulation Protocol
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2010-09. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist (drug) — also listed as: Suprefact nasal spray
GnRH antagonist (drug) — also listed as: Orgalutran or Cetrotide
hP-hMG (drug) — also listed as: Menopur
Human chorionic gonadotropin (drug) — also listed as: Pregnyl
Progesterone (drug) — also listed as: Utrogestan vaginal tablets

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Centre for Reproductive Medicine
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy

ClinicalTrials.gov · NCT01876004 · Registry updated: 2013-06-12

Condition / research focus: Ectopic Pregnancy
Sponsor: Federal University of São Paulo
Countries with listed sites: Brazil
Registry dates and results: Start: 2011-09. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Methotrexate (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Federal University of Sao Paulo
São Paulo, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803

ClinicalTrials.gov · NCT01851512 · Registry updated: 2013-05-16

Condition / research focus: Infertility; Induction of Ovulation
Sponsor: Dong-A Pharmaceutical Co., Ltd.
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-05. Completion: 2011-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

T-R (Test-Reference drug) (drug) — also listed as: Drug: DA-3803 (Test drug), Drug: Ovidrel liquid injection (Referecne drug)
R-T (Reference-Test drug) (drug) — also listed as: Drug: Ovidrel liquid injection (Referecne drug), Drug: DA-3803 (Test drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles

ClinicalTrials.gov · NCT01406600 · Registry updated: 2013-04-12

Condition / research focus: in Vitro Fertilization; Poor Responder
Sponsor: Seoul National University Hospital
Countries with listed sites: South Korea
Registry dates and results: Start: 2011-09. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant hCG (Ovidrel®) (drug)

Where the study takes place — 1 listed sites

Seoul National University Hospital
Seoul, South Korea
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles

ClinicalTrials.gov · NCT01780610 · Registry updated: 2013-04-02

Condition / research focus: Infertility
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Countries with listed sites: China
Registry dates and results: Start: 2012-01. Completion: 2015-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Letrozole and human chorionic gonadotrophin (drug) — also listed as: Letrozole tablets, HCG, Chorionic gonadotrophin, Chorionic gonadotropic hormone
estradiol and progesterone (drug) — also listed as: Estradiol Valerate, Progynova, 3,20-pregnene-4; 4-pregnene-3,20-dione, corpus luteum hormone, luteal hormone

Where the study takes place — 1 listed sites

Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

ClinicalTrials.gov · NCT00042952 · Registry updated: 2013-01-17

Condition / research focus: Ovarian Dysgerminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Ovarian Germ Cell Tumor; Stage II Malignant Testicular Germ Cell Tumor; Stage II Ovarian Germ Cell Tumor; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Testicular Seminoma
Sponsor: National Cancer Institute (NCI)
Countries with listed sites: United States
Registry dates and results: Start: 2002-06. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

imatinib mesylate (drug) — also listed as: CGP 57148, Gleevec, Glivec
therapeutic conventional surgery (procedure)
laboratory biomarker analysis (other)

Where the study takes place — 1 listed sites

Cancer and Leukemia Group B
Chicago, Illinois, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)

ClinicalTrials.gov · NCT01768247 · Registry updated: 2013-01-17

Condition / research focus: Endometrial Thickness; Pregnancy Outcome
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Greece
Registry dates and results: Start: 2012-01. Completion: 2014-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HCG (human chorionic gonadotropin) (drug)

Where the study takes place — 1 listed sites

HRG Foundation
Thessaloniki, Kalamaria, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Assessment of Implantation Potential of Embryos by Time-lapse Technology

ClinicalTrials.gov · NCT01760278 · Registry updated: 2013-01-04

Condition / research focus: Embryo/Fetus Death; Blastocyst Disintegration; Aneuploidy; Complication of Implant; Chemical Pregnancy
Sponsor: Bloom IVF and Fertility Centre
Countries with listed sites: India
Registry dates and results: Start: 2012-12. Completion: 2013-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant Follicle Stimulating Hormone (rFSH) (drug) — also listed as: Gonal-F, Progesterone vaginal, Ovitrell 250mcg, Cetrorelix 0.25 mg

Where the study takes place — 1 listed sites

Lilavati Hospital and Research Center, IVF department
Mumbai, Maharashtra, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Predicting Ovarian Response in Artificial Insemination With Low Stimulation

ClinicalTrials.gov · NCT01662180 · Registry updated: 2012-12-13

Condition / research focus: Subfertility
Sponsor: Isala
Countries with listed sites: Netherlands
Registry dates and results: Start: 2012-12. Completion: 2015-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follicle Stimulating Hormone (drug) — also listed as: Puregon [Merck Sharp & Dohme bv], Gonal -F [Serono Benelux bv]

Where the study takes place — 7 listed sites

OLVG
Amsterdam, Po 95500, Netherlands
Site recruitment: Not yet recruiting
Isala Klinieken
Zwolle, PO Box 10400, Netherlands
Site recruitment: Recruiting
Catharina Ziekenhuis
Eindhoven, PO Box 1350, Netherlands
Site recruitment: Not yet recruiting
AMC
Amsterdam, PO Box 22660, Netherlands
Site recruitment: Not yet recruiting
VUMC
Amsterdam, PO Box 7057, Netherlands
Site recruitment: Not yet recruiting
UMC Utrecht
Utrecht, PO Box 85500, Netherlands
Site recruitment: Not yet recruiting
st Elizabeth Gasthuis
Tilburg, PO Box 90151, Netherlands
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Intra-uterine Injection of Human Chorionic Gonadotrophin (hCG) Before Embryo Transfer

ClinicalTrials.gov · NCT01030393 · Registry updated: 2012-08-21

Condition / research focus: Infertility
Sponsor: The Egyptian IVF-ET Center
Countries with listed sites: Egypt
Registry dates and results: Start: 2010-01. Completion: 2011-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotrophin (drug) — also listed as: choriomon

Where the study takes place — 1 listed sites

The Egyptian IVF- ET center
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1

ClinicalTrials.gov · NCT00883766 · Registry updated: 2012-07-20

Condition / research focus: Polycystic Ovary Syndrome; In Vitro Fertilization
Sponsor: Fundacion Dexeus
Countries with listed sites: Spain
Registry dates and results: Start: 2009-04. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Controlled ovarian hyperstimulation for IVF with a long agonist protocol (other)
Controlled ovarian hyperstimulation for IVF with an antagonist protocol (other)

Where the study takes place — 1 listed sites

Institut Universitari Dexeus
Barcelona, Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP

ClinicalTrials.gov · NCT01623570 · Registry updated: 2012-06-20

Condition / research focus: Hypogonadotropic Hypogonadism
Sponsor: Centro Riproduzione e Andrologia
Countries with listed sites: Italy
Registry dates and results: Start: 2011-03. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pergoveris: 150IU r-hFSH + 75IU r-hLH (drug) — also listed as: Pergoveris
Menopur: HMG-HP (150 IU) (drug) — also listed as: Menopur

Where the study takes place — 1 listed sites

Centro Riproduzione e Andrologia
Taranto, Italy, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers

ClinicalTrials.gov · NCT01009723 · Registry updated: 2012-06-08

Condition / research focus: Preterm Delivery
Sponsor: Esoterix Genetic Laboratories, LLC
Countries with listed sites: United States
Registry dates and results: Start: 2010-03. Completion: 2012-07 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 2 listed sites

Integrated Genetics
Westborough, Massachusetts, United States
Site recruitment: Not reported
Integrated Genetics
Santa Fe, New Mexico, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity

ClinicalTrials.gov · NCT01595334 · Registry updated: 2012-05-25

Condition / research focus: Infertility
Sponsor: Southern Cross Fertility Centre
Countries with listed sites: India
Registry dates and results: Start: 2012-04. Completion: 2012-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix (drug) — also listed as: Cetrotide
Luprolide Acetate (drug) — also listed as: Lupron

Where the study takes place — 3 listed sites

Sat Kaival Hospital Pvt. Ltd.
Anand, Gujarat, India
Site recruitment: Recruiting
Disha Fertility & Surgical Hospital
Indore, Madhya Pradesh, India
Site recruitment: Recruiting
Southern Cross Fertility Center
Mumbai, Maharashtra, India
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Medications in Patients With Hypogonadism

ClinicalTrials.gov · NCT01601327 · Registry updated: 2012-05-18

Condition / research focus: Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Gulhane School of Medicine
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2008-01. Completion: 2012-03 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Testosterone enanthate (Sustanon 250 mg) (drug)
Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU) (drug)
Testosteron gel (Testojel 50 mg) (drug)

Where the study takes place — 2 listed sites

Gulhane School of Medicine Dep. of Endocrine and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported
Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?

ClinicalTrials.gov · NCT00907725 · Registry updated: 2012-05-10

Condition / research focus: Medical Abortion
Sponsor: Planned Parenthood League of Massachusetts
Countries with listed sites: United States
Registry dates and results: Start: 2009-05. Completion: 2010-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

serum BhCG follow-up (other)
ultrasonographic follow-up (other)

Where the study takes place — 1 listed sites

Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer

ClinicalTrials.gov · NCT00884221 · Registry updated: 2012-04-20

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Belgium · Czechia · Denmark · Poland · Spain · Sweden · Turkey (Türkiye)
Registry dates and results: Start: 2009-07. Completion: 2011-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Highly purified menotrophin (drug) — also listed as: HP-hMG, MENOPUR
Recombinant FSH (drug) — also listed as: Follitrophin-beta, PUREGON, FOLLISTIM

Where the study takes place — 25 listed sites

ERASME Hospital
Anderlecht, Belgium
Site recruitment: Not reported
UZ Brussel
Brussels, Belgium
Site recruitment: Not reported
UZ Antwerpen
Edegem, Belgium
Site recruitment: Not reported
UZ Gent
Ghent, Belgium
Site recruitment: Not reported
IVF Institute
Pilsen, Czechia
Site recruitment: Not reported
ISCARE IVF a.s.
Prague, Czechia
Site recruitment: Not reported
Pronatal
Prague, Czechia
Site recruitment: Not reported
H:S Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Amtssygehuset Herlev
Herlev, Denmark
Site recruitment: Not reported
Sygehus Vestsjælland
Holbæk, Denmark
Site recruitment: Not reported
H:S Hvidovre Hospital
Hvidovre, Denmark
Site recruitment: Not reported
KRIOBANK
Bialystok, Poland
Site recruitment: Not reported
nOvum
Warsaw, Poland
Site recruitment: Not reported
IU Dexeus
Barcelona, Spain
Site recruitment: Not reported
GINEFIV, Madrid
Madrid, Spain
Site recruitment: Not reported
IVI Madrid
Madrid, Spain
Site recruitment: Not reported
Ginemed
Seville, Spain
Site recruitment: Not reported
IVI Sevilla
Seville, Spain
Site recruitment: Not reported
IVI Valencia
Valencia, Spain
Site recruitment: Not reported
Fertilitetscentrum AB Gothenburg
Gothenburg, Sweden
Site recruitment: Not reported
IVF-kliniken CURA
Malmö, Sweden
Site recruitment: Not reported
RMC, Malmö
Malmö, Sweden
Site recruitment: Not reported
Hacettepe University
Ankara, Turkey (Türkiye)
Site recruitment: Not reported
American Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported
Memorial Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

ClinicalTrials.gov · NCT01004770 · Registry updated: 2012-04-05

Condition / research focus: Healthy
Sponsor: GE Healthcare
Countries with listed sites: United States
Registry dates and results: Start: 2009-10. Completion: 2010-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GE-145 (AN113111) Injection (drug) — also listed as: AH113111, GE-145
Visipaque (iodixanol) Injection (drug) — also listed as: Visipaque, Iodixanol

Where the study takes place — 1 listed sites

GE Healthcare
Princeton, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

ClinicalTrials.gov · NCT00805935 · Registry updated: 2012-01-27

Condition / research focus: Polycystic Ovarian Syndrome; Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2009-01. Completion: 2010-09 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menotropin (drug) — also listed as: Menopur®
Progesterone vaginal insert (drug) — also listed as: Endometrin®
Follitropin beta (drug) — also listed as: Follistim Pen®
Progesterone in oil (drug)
leuprolide acetate (drug) — also listed as: Lupron

Where the study takes place — 6 listed sites

Conceptions Reproductive Associates of Colorado
Littleton, Colorado, United States
Site recruitment: Not reported
Women's Medical Research Group LLC, Florida
Clearwater, Florida, United States
Site recruitment: Not reported
Fertility Center of Illinois
Chicago, Illinois, United States
Site recruitment: Not reported
Weill Cornell Medical College
New York, New York, United States
Site recruitment: Not reported
Women & Infants' Hospital of RI
Providence, Rhode Island, United States
Site recruitment: Not reported
Center for Assisted Reproduction
Bedford, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Proteomics & Glyco-Proteomic Analysis of Follicular Fluid

ClinicalTrials.gov · NCT01487486 · Registry updated: 2011-12-07

Condition / research focus: Polycystic Ovary Syndrome; Normal Volunteers
Sponsor: University of Cincinnati
Countries with listed sites: United States
Registry dates and results: Start: 2011-12. Completion: 2014-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IVF Antagonist Protocol (drug)

Where the study takes place — 1 listed sites

Center for Reproductive Health
Cincinnati, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 20:51 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

ClinicalTrials.gov · NCT01888744 · Registry updated: 2013-06-28

Condition / research focus: Reproductive Endocrinology; Fertility; Optimal Stimulation Protocol
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2010-09. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist (drug) — also listed as: Suprefact nasal spray
GnRH antagonist (drug) — also listed as: Orgalutran or Cetrotide
hP-hMG (drug) — also listed as: Menopur
Human chorionic gonadotropin (drug) — also listed as: Pregnyl
Progesterone (drug) — also listed as: Utrogestan vaginal tablets

Where the study takes place — 1 listed sites

Centre for Reproductive Medicine
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy

ClinicalTrials.gov · NCT01876004 · Registry updated: 2013-06-12

Condition / research focus: Ectopic Pregnancy
Sponsor: Federal University of São Paulo
Countries with listed sites: Brazil
Registry dates and results: Start: 2011-09. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Methotrexate (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Federal University of Sao Paulo
São Paulo, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803

ClinicalTrials.gov · NCT01851512 · Registry updated: 2013-05-16

Condition / research focus: Infertility; Induction of Ovulation
Sponsor: Dong-A Pharmaceutical Co., Ltd.
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-05. Completion: 2011-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

T-R (Test-Reference drug) (drug) — also listed as: Drug: DA-3803 (Test drug), Drug: Ovidrel liquid injection (Referecne drug)
R-T (Reference-Test drug) (drug) — also listed as: Drug: Ovidrel liquid injection (Referecne drug), Drug: DA-3803 (Test drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles

ClinicalTrials.gov · NCT01406600 · Registry updated: 2013-04-12

Condition / research focus: in Vitro Fertilization; Poor Responder
Sponsor: Seoul National University Hospital
Countries with listed sites: South Korea
Registry dates and results: Start: 2011-09. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant hCG (Ovidrel®) (drug)

Where the study takes place — 1 listed sites

Seoul National University Hospital
Seoul, South Korea
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles

ClinicalTrials.gov · NCT01780610 · Registry updated: 2013-04-02

Condition / research focus: Infertility
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Countries with listed sites: China
Registry dates and results: Start: 2012-01. Completion: 2015-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Letrozole and human chorionic gonadotrophin (drug) — also listed as: Letrozole tablets, HCG, Chorionic gonadotrophin, Chorionic gonadotropic hormone
estradiol and progesterone (drug) — also listed as: Estradiol Valerate, Progynova, 3,20-pregnene-4; 4-pregnene-3,20-dione, corpus luteum hormone, luteal hormone

Where the study takes place — 1 listed sites

Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

ClinicalTrials.gov · NCT00042952 · Registry updated: 2013-01-17

Condition / research focus: Ovarian Dysgerminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Ovarian Germ Cell Tumor; Stage II Malignant Testicular Germ Cell Tumor; Stage II Ovarian Germ Cell Tumor; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Testicular Seminoma
Sponsor: National Cancer Institute (NCI)
Countries with listed sites: United States
Registry dates and results: Start: 2002-06. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

imatinib mesylate (drug) — also listed as: CGP 57148, Gleevec, Glivec
therapeutic conventional surgery (procedure)
laboratory biomarker analysis (other)

Where the study takes place — 1 listed sites

Cancer and Leukemia Group B
Chicago, Illinois, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)

ClinicalTrials.gov · NCT01768247 · Registry updated: 2013-01-17

Condition / research focus: Endometrial Thickness; Pregnancy Outcome
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Greece
Registry dates and results: Start: 2012-01. Completion: 2014-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HCG (human chorionic gonadotropin) (drug)

Where the study takes place — 1 listed sites

HRG Foundation
Thessaloniki, Kalamaria, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Assessment of Implantation Potential of Embryos by Time-lapse Technology

ClinicalTrials.gov · NCT01760278 · Registry updated: 2013-01-04

Condition / research focus: Embryo/Fetus Death; Blastocyst Disintegration; Aneuploidy; Complication of Implant; Chemical Pregnancy
Sponsor: Bloom IVF and Fertility Centre
Countries with listed sites: India
Registry dates and results: Start: 2012-12. Completion: 2013-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant Follicle Stimulating Hormone (rFSH) (drug) — also listed as: Gonal-F, Progesterone vaginal, Ovitrell 250mcg, Cetrorelix 0.25 mg

Where the study takes place — 1 listed sites

Lilavati Hospital and Research Center, IVF department
Mumbai, Maharashtra, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Predicting Ovarian Response in Artificial Insemination With Low Stimulation

ClinicalTrials.gov · NCT01662180 · Registry updated: 2012-12-13

Condition / research focus: Subfertility
Sponsor: Isala
Countries with listed sites: Netherlands
Registry dates and results: Start: 2012-12. Completion: 2015-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follicle Stimulating Hormone (drug) — also listed as: Puregon [Merck Sharp & Dohme bv], Gonal -F [Serono Benelux bv]

Where the study takes place — 7 listed sites

OLVG
Amsterdam, Po 95500, Netherlands
Site recruitment: Not yet recruiting
Isala Klinieken
Zwolle, PO Box 10400, Netherlands
Site recruitment: Recruiting
Catharina Ziekenhuis
Eindhoven, PO Box 1350, Netherlands
Site recruitment: Not yet recruiting
AMC
Amsterdam, PO Box 22660, Netherlands
Site recruitment: Not yet recruiting
VUMC
Amsterdam, PO Box 7057, Netherlands
Site recruitment: Not yet recruiting
UMC Utrecht
Utrecht, PO Box 85500, Netherlands
Site recruitment: Not yet recruiting
st Elizabeth Gasthuis
Tilburg, PO Box 90151, Netherlands
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Intra-uterine Injection of Human Chorionic Gonadotrophin (hCG) Before Embryo Transfer

ClinicalTrials.gov · NCT01030393 · Registry updated: 2012-08-21

Condition / research focus: Infertility
Sponsor: The Egyptian IVF-ET Center
Countries with listed sites: Egypt
Registry dates and results: Start: 2010-01. Completion: 2011-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotrophin (drug) — also listed as: choriomon

Where the study takes place — 1 listed sites

The Egyptian IVF- ET center
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1

ClinicalTrials.gov · NCT00883766 · Registry updated: 2012-07-20

Condition / research focus: Polycystic Ovary Syndrome; In Vitro Fertilization
Sponsor: Fundacion Dexeus
Countries with listed sites: Spain
Registry dates and results: Start: 2009-04. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Controlled ovarian hyperstimulation for IVF with a long agonist protocol (other)
Controlled ovarian hyperstimulation for IVF with an antagonist protocol (other)

Where the study takes place — 1 listed sites

Institut Universitari Dexeus
Barcelona, Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP

ClinicalTrials.gov · NCT01623570 · Registry updated: 2012-06-20

Condition / research focus: Hypogonadotropic Hypogonadism
Sponsor: Centro Riproduzione e Andrologia
Countries with listed sites: Italy
Registry dates and results: Start: 2011-03. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pergoveris: 150IU r-hFSH + 75IU r-hLH (drug) — also listed as: Pergoveris
Menopur: HMG-HP (150 IU) (drug) — also listed as: Menopur

Where the study takes place — 1 listed sites

Centro Riproduzione e Andrologia
Taranto, Italy, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers

ClinicalTrials.gov · NCT01009723 · Registry updated: 2012-06-08

Condition / research focus: Preterm Delivery
Sponsor: Esoterix Genetic Laboratories, LLC
Countries with listed sites: United States
Registry dates and results: Start: 2010-03. Completion: 2012-07 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 2 listed sites

Integrated Genetics
Westborough, Massachusetts, United States
Site recruitment: Not reported
Integrated Genetics
Santa Fe, New Mexico, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity

ClinicalTrials.gov · NCT01595334 · Registry updated: 2012-05-25

Condition / research focus: Infertility
Sponsor: Southern Cross Fertility Centre
Countries with listed sites: India
Registry dates and results: Start: 2012-04. Completion: 2012-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix (drug) — also listed as: Cetrotide
Luprolide Acetate (drug) — also listed as: Lupron

Where the study takes place — 3 listed sites

Sat Kaival Hospital Pvt. Ltd.
Anand, Gujarat, India
Site recruitment: Recruiting
Disha Fertility & Surgical Hospital
Indore, Madhya Pradesh, India
Site recruitment: Recruiting
Southern Cross Fertility Center
Mumbai, Maharashtra, India
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Medications in Patients With Hypogonadism

ClinicalTrials.gov · NCT01601327 · Registry updated: 2012-05-18

Condition / research focus: Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Gulhane School of Medicine
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2008-01. Completion: 2012-03 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Testosterone enanthate (Sustanon 250 mg) (drug)
Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU) (drug)
Testosteron gel (Testojel 50 mg) (drug)

Where the study takes place — 2 listed sites

Gulhane School of Medicine Dep. of Endocrine and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported
Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?

ClinicalTrials.gov · NCT00907725 · Registry updated: 2012-05-10

Condition / research focus: Medical Abortion
Sponsor: Planned Parenthood League of Massachusetts
Countries with listed sites: United States
Registry dates and results: Start: 2009-05. Completion: 2010-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

serum BhCG follow-up (other)
ultrasonographic follow-up (other)

Where the study takes place — 1 listed sites

Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer

ClinicalTrials.gov · NCT00884221 · Registry updated: 2012-04-20

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Belgium · Czechia · Denmark · Poland · Spain · Sweden · Turkey (Türkiye)
Registry dates and results: Start: 2009-07. Completion: 2011-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Highly purified menotrophin (drug) — also listed as: HP-hMG, MENOPUR
Recombinant FSH (drug) — also listed as: Follitrophin-beta, PUREGON, FOLLISTIM

Where the study takes place — 25 listed sites

ERASME Hospital
Anderlecht, Belgium
Site recruitment: Not reported
UZ Brussel
Brussels, Belgium
Site recruitment: Not reported
UZ Antwerpen
Edegem, Belgium
Site recruitment: Not reported
UZ Gent
Ghent, Belgium
Site recruitment: Not reported
IVF Institute
Pilsen, Czechia
Site recruitment: Not reported
ISCARE IVF a.s.
Prague, Czechia
Site recruitment: Not reported
Pronatal
Prague, Czechia
Site recruitment: Not reported
H:S Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Amtssygehuset Herlev
Herlev, Denmark
Site recruitment: Not reported
Sygehus Vestsjælland
Holbæk, Denmark
Site recruitment: Not reported
H:S Hvidovre Hospital
Hvidovre, Denmark
Site recruitment: Not reported
KRIOBANK
Bialystok, Poland
Site recruitment: Not reported
nOvum
Warsaw, Poland
Site recruitment: Not reported
IU Dexeus
Barcelona, Spain
Site recruitment: Not reported
GINEFIV, Madrid
Madrid, Spain
Site recruitment: Not reported
IVI Madrid
Madrid, Spain
Site recruitment: Not reported
Ginemed
Seville, Spain
Site recruitment: Not reported
IVI Sevilla
Seville, Spain
Site recruitment: Not reported
IVI Valencia
Valencia, Spain
Site recruitment: Not reported
Fertilitetscentrum AB Gothenburg
Gothenburg, Sweden
Site recruitment: Not reported
IVF-kliniken CURA
Malmö, Sweden
Site recruitment: Not reported
RMC, Malmö
Malmö, Sweden
Site recruitment: Not reported
Hacettepe University
Ankara, Turkey (Türkiye)
Site recruitment: Not reported
American Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported
Memorial Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

ClinicalTrials.gov · NCT01004770 · Registry updated: 2012-04-05

Condition / research focus: Healthy
Sponsor: GE Healthcare
Countries with listed sites: United States
Registry dates and results: Start: 2009-10. Completion: 2010-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GE-145 (AN113111) Injection (drug) — also listed as: AH113111, GE-145
Visipaque (iodixanol) Injection (drug) — also listed as: Visipaque, Iodixanol

Where the study takes place — 1 listed sites

GE Healthcare
Princeton, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

ClinicalTrials.gov · NCT00805935 · Registry updated: 2012-01-27

Condition / research focus: Polycystic Ovarian Syndrome; Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2009-01. Completion: 2010-09 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menotropin (drug) — also listed as: Menopur®
Progesterone vaginal insert (drug) — also listed as: Endometrin®
Follitropin beta (drug) — also listed as: Follistim Pen®
Progesterone in oil (drug)
leuprolide acetate (drug) — also listed as: Lupron

Where the study takes place — 6 listed sites

Conceptions Reproductive Associates of Colorado
Littleton, Colorado, United States
Site recruitment: Not reported
Women's Medical Research Group LLC, Florida
Clearwater, Florida, United States
Site recruitment: Not reported
Fertility Center of Illinois
Chicago, Illinois, United States
Site recruitment: Not reported
Weill Cornell Medical College
New York, New York, United States
Site recruitment: Not reported
Women & Infants' Hospital of RI
Providence, Rhode Island, United States
Site recruitment: Not reported
Center for Assisted Reproduction
Bedford, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Proteomics & Glyco-Proteomic Analysis of Follicular Fluid

ClinicalTrials.gov · NCT01487486 · Registry updated: 2011-12-07

Condition / research focus: Polycystic Ovary Syndrome; Normal Volunteers
Sponsor: University of Cincinnati
Countries with listed sites: United States
Registry dates and results: Start: 2011-12. Completion: 2014-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IVF Antagonist Protocol (drug)

Where the study takes place — 1 listed sites

Center for Reproductive Health
Cincinnati, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →